Karol E Watson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8932662/publications.pdf

Version: 2024-02-01

173 papers 22,806 citations

50276 46 h-index 148 g-index

180 all docs 180 docs citations

180 times ranked 26884 citing authors

#	Article	IF	CITATIONS
1	A comparative analysis of premature heart disease- and cancer-related mortality in women in the USA, 1999–2018. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 315-323.	4.0	25
2	Racial/ethnic health disparities in cardiovascular disease during the COVID-19 pandemic: revisiting a long-lasting problem. Cardiovascular Research, 2022, 118, e8-e10.	3.8	4
3	Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis. American Journal of Clinical Nutrition, 2022, 115, 914-924.	4.7	5
4	Health Consequences of Segregation and Disenfranchisement. Journal of the American Heart Association, 2022, 11 , e024772.	3.7	3
5	Association of Intensive Blood Pressure Control and Living Arrangement on Cardiovascular Outcomes by Race. JAMA Network Open, 2022, 5, e222037.	5.9	1
6	Cardiovascular Disease Mortality Among Hispanic Versus Nonâ€Hispanic White Adults in the United States, 1999 to 2018. Journal of the American Heart Association, 2022, 11, e022857.	3.7	17
7	Relationship Between Age at Menopause, Obesity, and Incident Heart Failure: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 2022, 11, e024461.	3.7	7
8	Sex-Specific Risk Factors Associated With First Acute Myocardial Infarction in Young Adults. JAMA Network Open, 2022, 5, e229953.	5.9	21
9	Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation, 2022, 145, 1632-1641.	1.6	60
10	Racial and Ethnic Differences in All-Cause and Cardiovascular Disease Mortality: The MESA Study. Circulation, 2022, 146, 229-239.	1.6	39
11	Working Agenda for Black Mothers. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007643.	2.2	34
12	Which came first, obstructive sleep apnoea or hypertension? A retrospective study of electronic records over 10 years, with separation by sex. BMJ Open, 2021, 11, e041179.	1.9	1
13	Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4746-e4765.	3.6	4
14	Mechanisms and Treatment of Dyslipidemia in Diabetes. Current Cardiology Reports, 2021, 23, 26.	2.9	39
15	Women in Cardiology Twitter Network: An Analysis of a Global Professional Virtual Community From 2016 to 2019. Journal of the American Heart Association, 2021, 10, e019321.	3.7	17
16	Sex Differences in the Association of Body Composition and Cardiovascular Mortality. Journal of the American Heart Association, 2021, 10, e017511.	3.7	21
17	The Multi-Ethnic Study of Atherosclerosis individual response to vitamin D trial: Building a randomized clinical trial into an observational cohort study. Contemporary Clinical Trials, 2021, 103, 106318.	1.8	1
18	Disparities in Cardiovascular Medicine. Circulation, 2021, 143, 2319-2320.	1.6	11

#	Article	IF	Citations
19	Mindfulness effects on lifestyle behavior and blood pressure: A randomized controlled trial. Health Science Reports, 2021, 4, e296.	1.5	12
20	Urinary Stress Hormones, Hypertension, and Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis. Hypertension, 2021, 78, 1640-1647.	2.7	21
21	Left Atrioventricular Coupling Index as a Prognostic Marker of Cardiovascular Events: The MESA Study. Hypertension, 2021, 78, 661-671.	2.7	33
22	Call to Action: Maternal Health and Saving Mothers: A Policy Statement From the American Heart Association. Circulation, 2021, 144, e251-e269.	1.6	51
23	National Trends and Disparities in Hospitalization for Acute Hypertension Among Medicare Beneficiaries (1999–2019). Circulation, 2021, 144, 1683-1693.	1.6	11
24	Race/ethnicity, neighborhood socioeconomic status and cardio-metabolic risk. SSM - Population Health, 2020, 11, 100634.	2.7	8
25	Race, Ancestry, and Vitamin D Metabolism: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4337-e4350.	3.6	38
26	Disparities in Cardiovascular Medicine: Circulation's Response. Circulation, 2020, 142, 1127-1128.	1.6	3
27	Serum Aldosterone Concentration, Blood Pressure, and Coronary Artery Calcium. Hypertension, 2020, 76, 113-120.	2.7	42
28	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA - Journal of the American Medical Association, 2020, 323, 2268.	7.4	104
29	If You Can't See It, You Can't Be It. JACC: Case Reports, 2020, 2, 840-842.	0.6	3
30	Reproducibility and Changes in Vena Caval Blood Flow by Using 4D Flow MRI in Pulmonary Emphysema and Chronic Obstructive Pulmonary Disease (COPD): The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Substudy. Radiology, 2019, 292, 585-594.	7.3	12
31	Change in left atrial function predicts incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. European Heart Journal Cardiovascular Imaging, 2019, 20, 979-987.	1.2	43
32	Risk factors for development of aminoglycoside resistance among gram-negative rods. American Journal of Health-System Pharmacy, 2019, 76, 1838-1847.	1.0	6
33	Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods. Open Forum Infectious Diseases, 2019, 6, ofz027.	0.9	19
34	Cardiovascular Care in Women Veterans. Circulation, 2019, 139, 1102-1109.	1.6	24
35	Sex Hormones and Measures of Kidney Function in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1171-1180.	3.6	12
36	Interleukin-10 as a predictor of major adverse cardiovascular events in a racially and ethnically diverse population: Multi-Ethnic Study of Atherosclerosis. Annals of Epidemiology, 2019, 30, 9-14.e1.	1.9	10

3

#	Article	IF	CITATIONS
37	Contribution of the in-vehicle microenvironment to individual ambient-source nitrogen dioxide exposure: the Multi-Ethnic Study of Atherosclerosis and Air Pollution. Journal of Exposure Science and Environmental Epidemiology, 2018, 28, 371-380.	3.9	11
38	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e30-e66.	1.6	500
39	Human airway branch variation and chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E974-E981.	7.1	80
40	A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema-like Lung Characteristics on CT Imaging. Chest, 2018, 154, 41-50.	0.8	28
41	Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). European Heart Journal, 2018, 39, 2401-2408.	2.2	383
42	Prognostic Significance of Large Airway Dimensions on Computed Tomography in the General Population. The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Annals of the American Thoracic Society, 2018, 15, 718-727.	3.2	24
43	The Great Recession worsened blood pressure and blood glucose levels in American adults. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3296-3301.	7.1	27
44	Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort study. Thorax, 2018, 73, 486-488.	5.6	19
45	A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts. Journal of Visualized Experiments, 2018, , .	0.3	4
46	Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association. Circulation, 2018, 138, e1-e34.	1.6	316
47	Coronary Calcium Score and Cardiovascular Risk. Journal of the American College of Cardiology, 2018, 72, 434-447.	2.8	570
48	Identifying Patients for Nonstatin Therapy. Reviews in Cardiovascular Medicine, 2018, 19, S1-S8.	1.4	8
49	Statin Intolerance. Reviews in Cardiovascular Medicine, 2018, 19, S9-S19.	1.4	2
50	Statin Intolerance. Reviews in Cardiovascular Medicine, 2018, 19, 9-19.	1.4	9
51	Identifying Patients for Nonstatin Therapy. Reviews in Cardiovascular Medicine, 2018, 19, 1-8.	1.4	7
52	Reflection Magnitude, a Measure of Arterial Stiffness, Predicts Incident Heart Failure in Men But Not Women: Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Cardiac Failure, 2017, 23, 353-362.	1.7	15
53	Lung function, percent emphysema, and QT duration: The Multi-Ethnic Study of Atherosclerosis (MESA) lung study. Respiratory Medicine, 2017, 123, 1-7.	2.9	12

Neighborhoods and racial/ethnic differences in ideal cardiovascular health (the Multi-Ethnic Study) Tj ETQq $0\ 0\ 0\ rg \ 8.3$ Overlock 10 Tf 50 and 10 Tf 50 and 10 Tf 50 to 10 Tf 50 to

#	Article	IF	Citations
55	Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study. Annals of the American Thoracic Society, 2017, 14, 649-658.	3.2	45
56	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax, 2017, 72, 472-474.	5.6	29
57	Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care, 2017, 40, 958-965.	8.6	50
58	Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. Circulation, 2017, 136, 52-64.	1.6	97
59	Individualized Knowledge Graph. Circulation Research, 2017, 120, 1078-1080.	4.5	17
60	Relation of Stress Hormones (Urinary Catecholamines/Cortisol) to Coronary Artery Calcium in Men Versus Women (from the Multi-Ethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology, 2017, 119, 1963-1971.	1.6	16
61	Triglycerides: A reappraisal. Trends in Cardiovascular Medicine, 2017, 27, 428-432.	4.9	12
62	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FHâ,,¢ patient registry. Atherosclerosis, 2017, 267, 19-26.	0.8	64
63	Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Research and Care, 2017, 5, e000438.	2.8	97
64	Closing the Remaining Evidence Gap. Circulation, 2017, 136, 1892-1894.	1.6	0
65	MY APPROACH to the Patient With Memory Loss Who Needs a Statin. Trends in Cardiovascular Medicine, 2017, 27, 158-159.	4.9	0
66	Curation and Phenotyping of Cardiovascular Case Reports Achieved by ICD Based Index System and MeSH Supported Query Platform. Journal of Molecular and Cellular Cardiology, 2017, 112, 167.	1.9	0
67	Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study. PLoS ONE, 2017, 12, e0176180.	2.5	50
68	Endothelial progenitor cells in chronic obstructive pulmonary disease and emphysema. PLoS ONE, 2017, 12, e0173446.	2.5	20
69	Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study. Maturitas, 2016, 91, 147-152.	2.4	2
70	Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program. Circulation: Cardiovascular Genetics, 2016, 9, 495-503.	5.1	5
71	Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study. Lancet, The, 2016, 388, 696-704.	13.7	404
72	Heart Failure Therapies for End-Stage Chemotherapy–Induced Cardiomyopathy. Journal of Cardiac Failure, 2016, 22, 439-448.	1.7	31

#	Article	IF	CITATIONS
73	Connecting the Dots. Circulation, 2016, 134, 362-364.	1.6	18
74	Acute Myocardial Infarction in Women. Circulation, 2016, 133, 916-947.	1.6	858
75	The 2013 ACC/AHA Cholesterol Treatment Guidelines: Applicability to Patients with Diabetes. Current Diabetes Reports, 2016, 16, 13.	4.2	10
76	Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. Future Oncology, 2016, 12, 855-870.	2.4	27
77	Slippery Slope of Triglycerides. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 97-99.	2.2	4
78	Diabetes and Clinical and Subclinical CVD. Global Heart, 2016, 11, 337.	2.3	29
79	Acculturation is associated with left ventricular mass in a multiethnic sample: the Multi-Ethnic Study of Atherosclerosis. BMC Cardiovascular Disorders, 2015, 15, 161.	1.7	7
80	A Systematic Assessment of the Association of Polysomnographic Indices with Blood Pressure: The Multi-Ethnic Study of Atherosclerosis (MESA). Sleep, 2015, 38, 587-596.	1.1	40
81	Association of menopause age and N-terminal pro brain natriuretic peptide. Menopause, 2015, 22, 527-533.	2.0	12
82	Pulmonary Microvascular Blood Flow in Mild Chronic Obstructive Pulmonary Disease and Emphysema. The MESA COPD Study. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 570-580.	5.6	127
83	Association of subclinical atherosclerosis using carotid intima-media thickness, carotid plaque, and coronary calcium score with left ventricular dyssynchrony: The multi-ethnic Study of Atherosclerosis. Atherosclerosis, 2015, 239, 412-418.	0.8	20
84	Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry*â€. Journal of Clinical Lipidology, 2015, 9, 451-452.	1.5	0
85	Should vascular effects of newer treatments be addressed more completely?. Future Oncology, 2015, 11, 1995-1998.	2.4	11
86	Ability of Reduced Lung Function to Predict Development of Atrial Fibrillation in Persons Aged 45 to 84 Years (fromAthe Multi-Ethnic Study of Atherosclerosis-Lung Study). American Journal of Cardiology, 2015, 115, 1700-1704.	1.6	25
87	Longitudinal Associations Between Neighborhood Physical and Social Environments and Incident Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2015, 175, 1311.	5.1	234
88	Usefulness of N-terminal Pro–brain Natriuretic Peptide and Myocardial Perfusion in Asymptomatic Adults (fromÂthe Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2015, 115, 1341-1345.	1.6	19
89	Getting Guidelines Correct. Journal of the American College of Cardiology, 2015, 65, 2051-2052.	2.8	2
90	Harnessing the Heart of Big Data. Circulation Research, 2015, 116, 1115-1119.	4.5	54

#	Article	lF	CITATIONS
91	10-Year Coronary Heart Disease RiskÂPrediction Using Coronary Artery Calcium and Traditional Risk Factors. Journal of the American College of Cardiology, 2015, 66, 1643-1653.	2.8	490
92	Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Reviews in Cardiovascular Medicine, 2015, 16, 125-30.	1.4	1
93	Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Reviews in Cardiovascular Medicine, 2015, 16, 125-130.	1.4	1
94	Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 347.	0.9	0
95	APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema. European Respiratory Journal, 2014, 43, 1003-1017.	6.7	37
96	Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes. Diabetes Care, 2014, 37, 2253-2260.	8.6	39
97	Age at menopause and incident heart failure. Menopause, 2014, 21, 585-591.	2.0	74
98	Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis. American Journal of Hypertension, 2014, 27, 801-810.	2.0	49
99	A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2014, 66, 130-139.	5 . 6	103
100	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology, 2014, 63, 2889-2934.	2.8	3,414
101	Effects of Weight Loss, Weight Cycling, and Weight Loss Maintenance on Diabetes Incidence and Change in Cardiometabolic Traits in the Diabetes Prevention Program. Diabetes Care, 2014, 37, 2738-2745.	8.6	97
102	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation, 2014, 129, S1-45.	1.6	4,842
103	Abdominal Aortic Calcium, Coronary Artery Calcium, and Cardiovascular Morbidity and Mortality in the Multi-Ethnic Study of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1574-1579.	2.4	95
104	Advanced lipid testing: when, why, and in whom?. Reviews in Cardiovascular Medicine, 2014, 15, 310-7; quiz 318-9.	1.4	2
105	Advanced Lipid Testing: When, Why, and In Whom?. Reviews in Cardiovascular Medicine, 2014, 15, 310-319.	1.4	2
106	Reference ranges of PR duration and P-wave indices in individuals free of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Electrocardiology, 2013, 46, 702-706.	0.9	38
107	Genetic ancestry and the relationship of cigarette smoking to lung function and per cent emphysema in four race/ethnic groups: a cross-sectional study. Thorax, 2013, 68, 634-642.	5 . 6	30
108	Fine Particulate Air Pollution and the Progression of Carotid Intima-Medial Thickness: A Prospective Cohort Study from the Multi-Ethnic Study of Atherosclerosis and Air Pollution. PLoS Medicine, 2013, 10, e1001430.	8.4	162

7

#	Article	IF	CITATIONS
109	Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program. Diabetes Care, 2012, 35, 363-366.	8.6	101
110	Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet, The, 2012, 379, 2243-2251.	13.7	384
111	Comparison of the Racial/Ethnic Prevalence of Regular Aspirin Use for the Primary Prevention of Coronary Heart Disease from the Multi-Ethnic Study of Atherosclerosis. American Journal of Cardiology, 2011, 107, 41-46.	1.6	28
112	Cardiovascular Imaging for Assessing Cardiovascular Risk in Asymptomatic Men Versus Women. Circulation: Cardiovascular Imaging, 2011, 4, 8-15.	2.6	85
113	Sex Differences in Subclinical Atherosclerosis by Race/Ethnicity in the Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology, 2011, 174, 165-172.	3.4	14
114	Treatment of Heart Failure in African Americansâ€" A Call to Action. Journal of the National Medical Association, 2011, 103, 86-98.	0.8	15
115	Activated TLR Signaling in Atherosclerosis among Women with Lower Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis. PLoS ONE, 2011, 6, e21067.	2.5	20
116	Socioeconomic and race/ethnic differences in daily salivary cortisol profiles: The Multi-Ethnic Study of Atherosclerosis. Psychoneuroendocrinology, 2010, 35, 932-943.	2.7	194
117	Is neighborhood racial/ethnic composition associated with depressive symptoms? The multi-ethnic study of atherosclerosis. Social Science and Medicine, 2010, 71, 541-550.	3.8	99
118	Geographic Variation in Hypertension Prevalence Among Blacks and Whites: The Multi-Ethnic Study of Atherosclerosis. American Journal of Hypertension, 2010, 23, 46-53.	2.0	46
119	Percent Emphysema, Airflow Obstruction, and Impaired Left Ventricular Filling. New England Journal of Medicine, 2010, 362, 217-227.	27.0	473
120	Pitavastatin: the newest HMG-CoA reductase inhibitor. Reviews in Cardiovascular Medicine, 2010, 11, 26-32.	1.4	1
121	Pitavastatin: The Newest HMG-CoA Reductase Inhibitor. Reviews in Cardiovascular Medicine, 2010, 11, 26-32.	1.4	1
122	Amlodipine/Atorvastatin Singleâ€Pill Therapy for Blood Pressure and Lipid Goals in African Americans: Influence of the Metabolic Syndrome and Type 2 Diabetes Mellitus. Journal of Clinical Hypertension, 2009, 11, 585-593.	2.0	8
123	Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. American Heart Journal, 2009, 158, 1038-1045.	2.7	36
124	Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. Journal of the American Society of Hypertension, 2009, 3, 210-220.	2.3	15
125	Association of Salivary Cortisol Circadian Pattern With Cynical Hostility: Multi-Ethnic Study of Atherosclerosis. Psychosomatic Medicine, 2009, 71, 748-755.	2.0	34
126	Do Socioeconomic Gradients in Subclinical Atherosclerosis Vary According to Acculturation Level? Analyses of Mexican-Americans in the Multi-Ethnic Study of Atherosclerosis. Psychosomatic Medicine, 2009, 71, 756-762.	2.0	39

#	Article	IF	Citations
127	The JUPITER trial: How will it change clinical practice?. Reviews in Cardiovascular Medicine, 2009, 10, 91-6.	1.4	9
128	What is the evidence in favor of low-dose statin therapy in 2008?. Current Atherosclerosis Reports, 2008, 10, 33-38.	4.8	2
129	Improved Attainment of Blood Pressure and Cholesterol Goals Using Single-Pill Amlodipine/Atorvastatin in African Americans: The CAPABLE Trial. Mayo Clinic Proceedings, 2008, 83, 35-45.	3.0	48
130	Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups. New England Journal of Medicine, 2008, 358, 1336-1345.	27.0	2,498
131	Value of Urinary Albumin-to-Creatinine Ratio as a Predictor of Type 2 Diabetes in Pre-Diabetic Individuals. Diabetes Care, 2008, 31, 2344-2348.	8.6	32
132	Intensive Glycemic Control and Cardiovascular Disease Observations From the ACCORD Study. Diabetes, 2008, 57, 1163-1165.	0.6	29
133	Cardiovascular Risk Reduction among African Americans: A Call to Action. Journal of the National Medical Association, 2008, 100, 18-27.	0.8	16
134	Managing Cardiometabolic Risk. Critical Pathways in Cardiology, 2007, 6, 5-14.	0.5	6
135	Homocysteine lowering and cardiovascular events after acute myocardial infarction. Current Cardiovascular Risk Reports, 2007, 1, 95-96.	2.0	0
136	Quality Indicators for the Care of Ischemic Heart Disease in Vulnerable Elders. Journal of the American Geriatrics Society, 2007, 55, S366-72.	2.6	14
137	Adherence to best practices: How do patient race and gender affect physician performance?. Current Cardiovascular Risk Reports, 2007, 1 , $102-107$.	2.0	10
138	HDL function as a target of lipid-modifying therapy. Reviews in Cardiovascular Medicine, 2007, 8, 1-8.	1.4	4
139	Is aggressive or moderate lipid lowering more effective in slowing vascular calcification in postmenopausal women?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 20-21.	3.3	O
140	Hospital discharge treatments after an acute event: evidence for a systems approach to prevention. Coronary Artery Disease, 2006, 17, 239-241.	0.7	3
141	Surgical risk in patients with metabolic syndrome: Focus on lipids and hypertension. Current Cardiology Reports, 2006, 8, 433-438.	2.9	5
142	Comparison of Efficacy and Safety of Rosuvastatin Versus Atorvastatin in African-American Patients in a Six-Week Trial. American Journal of Cardiology, 2006, 97, 229-235.	1.6	66
143	The Metabolic Syndrome: Recognition and Management. Disease Management: DM, 2006, 9, 16-33.	1.0	16
144	Air pollution and heart disease. Reviews in Cardiovascular Medicine, 2006, 7, 44.	1.4	6

#	Article	lF	CITATIONS
145	Lowering levels of lipids and homocysteine. Reviews in Cardiovascular Medicine, 2006, 7, 248-50.	1.4	O
146	Treating to Low-Density Lipoprotein Goal. Critical Pathways in Cardiology, 2005, 4, 174-176.	0.5	0
147	Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting. Circulation, 2005, 111, 488-493.	1.6	91
148	High-Density Lipoprotein Function. Journal of the American College of Cardiology, 2005, 46, 1792-1798.	2.8	254
149	Novel serum markers for risk prediction in acute coronary syndromes. Reviews in Cardiovascular Medicine, 2005, 6, 59-60.	1.4	0
150	The past, present, and future of statin therapy. Reviews in Cardiovascular Medicine, 2005, 6, 129-39.	1.4	3
151	Anti-Inflammatory Properties of HDL. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 351-358.	5.7	34
152	The relationship between inflammation and atherosclerotic events. Reviews in Cardiovascular Medicine, 2004, 5, 66-8.	1.4	0
153	Cardiovascular disease in African Americans. Introduction. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 3, S1-2.	1.4	1
154	Pathobiology of atherosclerosis: are there racial and ethnic differences?. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 3, S14-21.	1.4	2
155	Cardiovascular disease in African Americans. Closing the knowledge, treatment, and outcome gap. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 3, S42-4.	1.4	1
156	Plasma lipoprotein concentrations in ethnic populations. Current Cardiology Reports, 2003, 5, 483-487.	2.9	6
157	Lessons learned from recent lipid-lowering trials: Why physicians should change clinical practice. Clinical Cornerstone, 2003, 5, S11-S17.	0.7	1
158	Therapeutic Lifestyle Changes for Hypertension and Cardiovascular Risk Reduction. Journal of Clinical Hypertension, 2003, 5, 32-37.	2.0	5
159	Multilineage Potential of Cells From the Artery Wall. Circulation, 2003, 108, 2505-2510.	1.6	336
160	Atherosclerosis in Type 2 Diabetes Mellitus: The Role of Insulin Resistance. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, 253-260.	2.0	50
161	In-hospital Initiation of Cardiovascular Protective Therapies to Improve Treatment Rates and Clinical Outcomes. Critical Pathways in Cardiology, 2003, 2, 61-70.	0.5	6
162	The Metabolic Syndrome in African Americans: a review. Ethnicity and Disease, 2003, 13, 414-28.	2.3	66

#	Article	IF	CITATIONS
163	Lipid abnormalities in insulin resistant states. Reviews in Cardiovascular Medicine, 2003, 4, 228-36.	1.4	39
164	Coronary Heart Disease in African Americans. Heart Disease (Hagerstown, Md), 2001, 3, 97-108.	1.3	127
165	Lipid lowering in high-risk populations: how low should we go?. Ethnicity and Disease, 2001, 11, 834-7.	2.3	0
166	Fibronectin and Collagen I Matrixes Promote Calcification of Vascular Cells in Vitro, Whereas Collagen IV Matrix Is Inhibitory. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1964-1971.	2.4	112
167	Ethnic Origin and Serum Levels of $1\hat{l}_{\pm}$,25-Dihydroxyvitamin D ₃ Are Independent Predictors of Coronary Calcium Mass Measured by Electron-Beam Computed Tomography. Circulation, 1997, 96, 1477-1481.	1.6	99
168	Active Serum Vitamin D Levels Are Inversely Correlated With Coronary Calcification. Circulation, 1997, 96, 1755-1760.	1.6	409
169	Role of Molecular Regulation in Vascular Calcification. Journal of Atherosclerosis and Thrombosis, 1996, 3, 90-94.	2.0	43
170	The atherosclerosis–calcification link?. Current Opinion in Lipidology, 1996, 7, 101-104.	2.7	25
171	Atherosclerotic calcification: Relation to developmental osteogenesis. American Journal of Cardiology, 1995, 75, 88B-91B.	1.6	94
172	Mechanism of calcification in atherosclerosis. Trends in Cardiovascular Medicine, 1994, 4, 45-49.	4.9	106
173	Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 1989, 339, 58-61.	27.8	1,782